Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 95 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ocrevus Clear all
Completed No phase listed Observational

Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis

NCT04676555
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
Ocrelizumab, Ofatumumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Oct 21, 2026, 9:58 AM EDT
Completed Phase 4 Interventional Results available

Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis

NCT04261790
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Ocrelizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 21, 2026, 9:58 AM EDT
Active, not recruiting Phase 4 Interventional

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

NCT05285891
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab, Placebo for Ocrelizumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
13
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 21, 2026, 9:58 AM EDT
Completed No phase listed Observational

Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation

NCT06668324
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 21, 2026, 9:58 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

NCT02545868
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
23-PPV, 13-PCV Booster, Influenza Vaccine, KLH, OCR, TT Vaccine
Biological · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
20
States / cities
Cullman, Alabama • Tucson, Arizona • Fullerton, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 21, 2026, 9:58 AM EDT
Completed No phase listed Observational

A Systems Approach to Understanding Disease Processes in Multiple Sclerosis

NCT05081700
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
All patients in the study will be treated with ocrelizumab
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Timeline
2020 – 2023
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 21, 2026, 9:58 AM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab

NCT04998851
View directory record Official record
Conditions
Multiple Sclerosis, Clinically Isolated Syndrome
Interventions
Ocrelizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
San Francisco, California • Aurora, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 21, 2026, 9:58 AM EDT
Completed Phase 3 Interventional Results available

Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab

NCT04175834
View directory record Official record
Conditions
Multiple Sclerosis, Infusion Reaction
Interventions
cetrizine, diphenhydramine
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 21, 2026, 9:58 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

NCT05123703
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Ocrelizumab, Ocrelizumab Placebo, Fingolimod, Fingolimod Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
10 Years to 17 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
10
States / cities
La Jolla, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 21, 2026, 9:58 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab

NCT00808210
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Infliximab, Methotrexate, Methylprednisolone, Ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
53
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Murrieta, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 21, 2026, 9:58 AM EDT
Completed No phase listed Observational

Ocrelizumab Effects on the Metabolome in MS

NCT03873389
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 21, 2026, 9:58 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

NCT04544449
View directory record Official record
Conditions
Multiple Sclerosis, Primary Progressive
Interventions
Fenebrutinib, Ocrelizumab, Placebo matched to ocrelizumab, Placebo matched to fenebrutinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
985 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
43
States / cities
Homewood, Alabama • Berkeley, California • Fullerton, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 21, 2026, 9:58 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Ocrelizumab in Autoimmune Encephalitis

NCT03835728
View directory record Official record
Conditions
Autoimmune Encephalitis
Interventions
Ocrelizumab, Saline
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 21, 2026, 9:58 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies

NCT05950308
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 21, 2026, 9:58 AM EDT
Active, not recruiting Phase 3 Interventional

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

NCT06700343
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions
Ocrelizumab (US), Ocrelizumab (EU), ABP 692
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
27
States / cities
Mobile, Alabama • Scottsdale, Arizona • Carlsbad, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 21, 2026, 9:58 AM EDT
Recruiting No phase listed Observational

People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

NCT07207148
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
GLP-1, Ocrelizumab (US)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 21, 2026, 9:58 AM EDT
Recruiting Phase 4 Interventional

Home Based Infusions for Ocrelizumab

NCT04650321
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab at home
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Centennial, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 21, 2026, 9:58 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis

NCT04925557
View directory record Official record
Conditions
Secondary-progressive Multiple Sclerosis
Interventions
Mayzent, Ocrevus
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 21, 2026, 9:58 AM EDT
Completed No phase listed Observational Results available

Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis

NCT03396822
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Gadoteridol
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 21, 2026, 9:58 AM EDT
Terminated No phase listed Observational

Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication

NCT04796584
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus
Other
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 21, 2026, 9:58 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

NCT02649985
View directory record Official record
Conditions
Multiple Sclerosis, Alzheimer's Disease
Interventions
[F-18]PBR06, [C-11]PBR28
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 21, 2026, 9:58 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis

NCT03138525
View directory record Official record
Conditions
Multiple Sclerosis, Healthy
Interventions
Blood sampling (MS), Blood sampling (controls)
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 21, 2026, 9:58 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab

NCT04837651
View directory record Official record
Conditions
Multiple Sclerosis, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Demyelinating Diseases, Autoimmune Diseases, Immune System Diseases, Pathologic Processes
Interventions
Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test, T-Detect COVID T-cell blood test
Device
Lead sponsor
Dragonfly Research, LLC
Other
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Wellesley, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 21, 2026, 9:58 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

NCT02637856
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Ocrelizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
67
States / cities
Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Oct 21, 2026, 9:58 AM EDT